Neonatal diabetes: The role of KCNJ11 (Kir6.2)

Endocrine Development

Volumn 11, Issue , 2007, Pages 70-82

  Tammaro, P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL;

BIOLOGICAL MODEL; CHEMICAL STRUCTURE; DIABETES MELLITUS; GENETICS; HUMAN; METABOLISM; MUTATION; NEWBORN; PANCREAS ISLET BETA CELL; PHYSIOLOGY; REVIEW;

DIABETES MELLITUS; HUMANS; INFANT, NEWBORN; INSULIN-SECRETING CELLS; KATP CHANNELS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION;

EID: 39549088569     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000111059     Document Type: Conference Paper

References (70)

1. + channels. Prog Biophys Mol Biol 2003;81:133-176.
2. Ashcroft FM, Harrison DE, Ashcroft SJ: Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984;312:446-448.
3. + channels and their probable role for the membrane potential of mouse motor nerve endings. Pflügers Arch 1992;421:292-294
4. Yamada K, Ji JJ, Yuan H, Miki T, Sato S, Horimoto N, Shimizu T, Seino S, Inagaki N: Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 2001;292:1543-1546.
5. Faivre JF, Findlay I: Action potential duration and activation of ATP-sensitive potassium current in isolated guinea pig ventricular myocytes. Biochim Biophys Acta 1990;1029:167-172.
6. ATP channels in health and disease. J Mol Cell Cardiol 2005;38:937-943.
7. + channel openers and glucose deprivation. J Physiol 1997;502:397-408.
8. Quayle JM, Nelson MT, Standen NB: ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:1165-1232.
9. ATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995;270:1166-1170.
10. ATP channel subunits. Neuron 1997;18:827-838.
11. ATP channel complex. J Gen Physiol 1997;110:655-664.
12. + channels in the absence of the sulphonylurea receptor. Nature 1997;387:179-183.
13. ATP channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit. Proc Natl Acad Sci USA 1998;95:13953-13958.
14. ATP channels. Science 1998;282:1138-1141.
15. ATP channels. Science 1998;282:1141-1144.
16. Gribble FM, Proks P, Corkey BE, Ashcroft FM: Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA. J Biol Chem 1998;273:26383-26387.
17. Branstrom R, Leibiger IB, Leibiger B, Corkey BE, Berggren PO, Larsson O: Long chain coenzyme A esters activate the pore-forming subunit (Kir6. 2) of the ATP-regulated potassium channel. J Biol Chem 1998;273:31395-31400.
18. Nichols CG, Shyng SL, Nestorowicz A, Glaser B, Clement JP, Gonzalez G, Aguilar-Bryan L, Permutt MA, Bryan J: Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 1996;272:1785-1787.
19. ATP channel activation by Mg-ADP and diazoxide. EMBO J 1997;16:1145-1152.
20. ATP channel activity by diazoxide and MgADP: distinct functions of the two nucleotide binding folds of the sulfonylurea receptor. J Gen Physiol 1997;110:643-654.
21. + conductance. Neuron 2001;31:233-245.
22. ATP channels in dopaminergic midbrain neurons. EMBO J 1999;18:833-846.
23. + channel. J Biol Chem 1996;271:24321-24324.
24. ATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. BMC Physiol 2005;5:1.
25. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP, Boyd AE 3rd, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA: Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-426.
26. Shi NQ, Ye B, Makielski JC: Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol 2005;39:51-60.
27. + currents expressed in Xenopus oocytes. J Physiol 1997;498:87-98.
28. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000;49:3-6.
29. ATP channel openers. Trends Pharmacol Sci 2000;21:439-445.
30. Gribble FM, Reimann F: Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003;46:875-891.
31. Edwards G, Weston AH: The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 1993;33:597-637.
32. Quast U: Potassium channel openers: pharmacological and clinical aspects. Fundam Clin Pharmacol 1992;6:279-293.
33. Ashcroft F, Rorsman P: Type 2 diabetes mellitus: not quite exciting enough? Hum Mol Genet 2004;1:21-31.
34. Temple IK, James RS, Crolla JA, Sitch FL, Jacobs PA, Howell WM, Betts P, Baum JD, Shield JP: An imprinted gene(s) for diabetes? Nat Genet 1995;9:110-112.
35. Gloyn AL, Reimann F, Girard C, Edghill EL, Proks P, Pearson ER, Temple IK, Mackay DJ, Shield JP, Freedenberg D, Noyes K, Ellard S, Ashcroft FM, Gribble FM, Hattersley AT: Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 2005;14:925-934.
36. Njolstad PR, Sovik O, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, Undlien DE, Shiota C, Magnuson MA, Molven A, Matschinsky FM, Bell GI: Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001;344:1588-1592.
37. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF: Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997;15:106-110.
38. Schwitzgebel VM, Mamin A, Brun T, Ritz-Laser B, Zaiko M, Maret A, Jornayvaz FR, Theintz GE, Michielin O, Melloul D, Philippe J: Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab 2003;88:4398-4406.
39. Roberts J, Searle J: Neonatal diabetes mellitus associated with severe diarrhea, hyperimmunoglobulin E syndrome, and absence of islets of Langerhans. Pediatr Pathol Lab Med 1995;15:477-483.
40. Jonsson J, Carlsson L, Edlund T, Edlund H: Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994;371:606-609.
41. Sellick GS, Barker KT, Stolte-Dijkstra I, Fleischmann C, Coleman RJ, Garrett C, Gloyn AL, Edghill EL, Hattersley AT, Wellauer PK, Goodwin G, Houlston RS: Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 2004;36:1301-1305.
42. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C: EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000;25:406-409.
43. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-466.
44. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, Colclough K, Hattersley AT, Ashcroft FM, Ellard S: A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006;15:1793-1800.
45. ATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med 2005;37:186-195.
46. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849.
47. Massa O, Iafusco D, D'Amato E, Gloyn AL, Hattersley AT, Pasquino B, Tonini G, Dammacco F, Zanette G, Meschi F, Porzio O, Bottazzo G, Crino A, Lorini R, Cerutti F, Vanelli M, Barbetti F: KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 2005;25:22-27.
48. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Sovik O, Njolstad PR X: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713-2718.
49. Ashcroft FM: ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 2005;115:2047-2058.
50. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT: Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 2006;49:1190-1197.
51. Hattersley AT, Ashcroft FM: Activating mutations in kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503-2513.
52. Zung A, Glaser B, Nimri R, Zadik Z: Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004;89: 5504-5507.
53. Yorifuji T, Nagashima K, Kurokawa K, Kawai M, Oishi M, Akazawa Y, Hosokawa M, Yamada Y, Inagaki N, Nakahata T: The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus. J Clin Endocrinol Metab 2005;90:3174-3178.
54. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM: Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA 2004;101:17539-17544.
55. Proks P, Girard C, Haider S, Gloyn AL, Hattersley AT, Sansom MS, Ashcroft FM: A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep 2005;6:470-475.
56. Tarasov AI, Welters HJ, Senkel S, Ryffel GU, Hattersley AT, Morgan NG, Ashcroft FM: A Kir6.2 mutation causing neonatal diabetes impairs electrical activity and insulin secretion from INS-1 beta-cells. Diabetes 2006;55:3075-3082.
57. Tammaro P, Girard C, Molnes J, Njolstad PR, Ashcroft FM: Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2-SUR1 interactions. EMBO J 2005;24:2318-2330.
58. Proks P, Girard C, Ashcroft FM: Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP. Hum Mol Genet 2005;14:2717-2726.
59. ATP channel Kir6.2 subunit. EMBO J 2005;24:229-239.
60. Shimomura K, Girard CA, Proks P, Nazim J, Lippiat JD, Cerutti F, Lorini R, Ellard S, Hattersely AT, Barbetti F, Ashcroft FM: Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects. Diabetes 2006;55:1705-1712.
61. Markworth E, Schwanstecher C, Schwanstecher M: ATP4- mediates closure of pancreatic betacell ATP-sensitive potassium channels by interaction with 1 of 4 identical sites. Diabetes 2000;49:1413-1418.
62. ATP channels induces profound neonatal diabetes. Cell 2000;100:645-654.
63. Griesemer D, Zawar C, Neumcke B: Cell-type specific depression of neuronal excitability in rat hippocampus by activation of ATP-sensitive potassium channels. Eur Biophys J 2002;31:467-477.
64. ATP channels. J Physiol 2006;571:3-14.
65. ATP channels by SUR1 and SUR2A. J Mol Cell Cardiol 2005;39:491-501.
66. Nichols CG, Lederer WJ: Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol 1991;261:H1675-H1686.
67. Sakura H, Ammala C, Smith PA, Gribble FM, Ashcroft FM: Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. FEBS Lett 1995;377:338-344.
68. Miki T, Minami K, Zhang L, Morita M, Gonoi T, Shiuchi T, Minokoshi Y, Renaud JM, Seino S: ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 2002;283:E1178-E1184.
69. Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT: High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 2005;28:758-759.
70. + channels in neonatal diabetes: implications for pharmacogenomic therapy. Diabetes 2005;54:2645-2654.